Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030
Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030
Eli Lilly和EVA Pharma達成協議，到2030年爲非洲49個低收入到中等收入國家的約20,000人擴大訪問Baricitinib的機會。
Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis, And Covid-19.
巴利西單抗由因塞特公司發現並授權給莉莉公司，用於治療類風溼性關節炎、斑禿、特應性皮炎和Covid-19。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間